- Home
- STRO
STRO
Sutro Biopharma Inc.
as 12-17-2024 4:00pm EST
Sutro Biopharma Inc is a clinical-stage drug discovery, development, and manufacturing company. It is mainly engaged in the development of biopharmaceutical products. The company manufactures next-generation protein therapeutics for cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF. Products offered by the company include STRO-001 for patients with multiple myeloma and non-Hodgkin lymphoma and STRO-002 for the treatment of ovarian and endometrial cancers.
| Founded: | 2003 | Country: | United States |
| Employees: | N/A | City: | SOUTH SAN FRANCISCO |
| Market Cap: | 172.8M | IPO Year: | 2018 |
| Target Price: | $12.14 | AVG Volume (30 days): | 1.4M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 7 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.73 | EPS Growth: | N/A |
| 52 Week Low/High: | $2.04 - $6.13 | Next Earning Date: | 11-13-2024 |
| Revenue: | $160,955,000 | Revenue Growth: | 230.90% |
| Revenue Growth (this year): | -60.85% | Revenue Growth (next year): | -8.34% |
Latest Sutro Biopharma Inc. News
STRO Breaking Stock News: Dive into STRO Ticker-Specific Updates for Smart Investing
GlobeNewswire
8 days ago
Sutro Biopharma Announces Selected Dose for Luvelta and Topline Results from Dose-Optimization Portion of REFRαME-O1 Trial in Platinum Resistant Ovarian Cancer
Zacks
a month ago
Sutro Biopharma (STRO) Upgraded to Buy: Here's What You Should Know
Simply Wall St.
a month ago
Sutro Biopharma Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag
Zacks
a month ago
Sutro Biopharma, Inc. (STRO) Reports Q3 Loss, Misses Revenue Estimates
GlobeNewswire
a month ago
Sutro Biopharma Reports Third Quarter 2024 Financial Results and Business Highlights
GlobeNewswire
a month ago
Sutro Biopharma Demonstrates Meaningful ADC Innovation with Five Presentations at the 15th Annual World ADC Conference
Clinical Trials Arena
a month ago
Sutro Biopharma begins trial of acute myeloid leukaemia treatment in children
MT Newswires
2 months ago
Sutro Biopharma Opens Enrollment for Luveltamab Tazevibulin Trial
Compare STRO vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "STRO Sutro Biopharma Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.